US pharma giant Merck & Co (NYSE: MRK) has announced the primary results of a placebo-controlled study of the cardiovascular safety of its DPP-4 inhibitor, Januvia (sitagliptin).
This already marketed drug generated first-quarter 2015 sales of $1.39 billion for Merck.
The Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) study achieved its primary composite CV endpoint of non-inferiority compared to usual care without sitagliptin. Non-inferiority was defined as the time to the first confirmed event of any of the following: CV-related death, nonfatal myocardial infarction (MI), nonfatal stroke, or hospitalization for unstable angina.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze